Illumina, Inc. (NASDAQ:ILMN) – Research analysts at Leerink Swann upped their Q3 2017 earnings estimates for Illumina in a report released on Tuesday. Leerink Swann analyst P. Souda now forecasts that the life sciences company will earn $1.01 per share for the quarter, up from their prior estimate of $0.99. Leerink Swann has a “Outperform” rating and a $225.00 price target on the stock.

A number of other brokerages also recently issued reports on ILMN. Argus lifted their price target on shares of Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a research note on Wednesday. Vetr downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $209.78 price target for the company. in a research note on Thursday, August 31st. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Barclays PLC reiterated an “equal weight” rating and issued a $150.00 price target on shares of Illumina in a research note on Wednesday, August 9th. Finally, Canaccord Genuity upgraded shares of Illumina from a “hold” rating to a “buy” rating and lifted their price target for the stock from $170.00 to $215.00 in a research note on Monday, August 7th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $181.76.

ILLEGAL ACTIVITY WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/14/q3-2017-earnings-forecast-for-illumina-inc-ilmn-issued-by-leerink-swann.html.

Shares of Illumina (NASDAQ:ILMN) opened at 213.43 on Thursday. The stock has a market cap of $31.16 billion, a PE ratio of 42.82 and a beta of 0.81. The company’s 50-day moving average is $194.72 and its 200-day moving average is $179.64. Illumina has a 52-week low of $119.37 and a 52-week high of $214.34.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $662.00 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter in the prior year, the company posted $0.86 earnings per share. Illumina’s revenue for the quarter was up 10.3% compared to the same quarter last year.

In other news, SVP Mostafa Ronaghi sold 20,000 shares of Illumina stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $210.00, for a total value of $4,200,000.00. Following the transaction, the senior vice president now directly owns 86,725 shares of the company’s stock, valued at approximately $18,212,250. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total transaction of $2,561,550.00. Following the completion of the transaction, the director now directly owns 534,176 shares in the company, valued at $91,221,235.52. The disclosure for this sale can be found here. Insiders sold a total of 165,705 shares of company stock worth $31,202,418 over the last ninety days. Corporate insiders own 1.60% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in ILMN. Winslow Capital Management LLC acquired a new position in Illumina in the 2nd quarter valued at $211,584,000. HPM Partners LLC increased its stake in Illumina by 29,103.8% in the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after buying an additional 749,424 shares during the period. Fred Alger Management Inc. increased its stake in Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after buying an additional 548,030 shares during the period. TIAA CREF Investment Management LLC increased its stake in Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after buying an additional 527,548 shares during the period. Finally, Capital World Investors increased its stake in Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares during the period. 93.34% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.